51 results about "Pre-Therapy" patented technology

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The invention discloses an in-vitro fertilization-based method and system for predicting the cumulative live productivity of multiple complete cycles, and the method comprises the steps: obtaining clinical data, embryo information and pregnancy follow-up visit data of a patient, and screening and preprocessing a sample in combination with a collection and discharge standard; feature variables are extracted before treatment, after treatment and at the early stage of pregnancy, an optimal set is determined, and key factors influencing live birth at all stages are accurately captured; after the nonlinear variables are processed by the RCS, a pre-treatment / post-treatment COX regression model and a Logistic regression model are adaptively constructed, and the prediction precision is improved by fitting data characteristics; and meanwhile, by evaluating the iterative optimization model, the variable weight is visually displayed by using a Nomogram graph after the model is qualified. The method can accurately predict the multi-cycle cumulative live productivity, assists a doctor in formulating a personalized scheme, helps a patient to reasonably plan treatment, reduces the time and economic burden of blind treatment, and has clinical practical value and benefits of the patient.

1. The name of the design product: computer with graphical user interface (computing medical accelerator tumor center bed coordinates). 2. The use of the design product: graphical user interface in the screen. 3. The design points of the design product: graphical user interface in the screen. 4. The picture or photo that best shows the design points: front view. 5. The use of the graphical user interface: quickly and accurately calculate the coordinates of the accelerator bed corresponding to the tumor center of the tumor radiotherapy patient, and submit the coordinates to the radiotherapy technician to complete the accurate pre-treatment repositioning bed. 6. The human-computer interaction mode of the graphical user interface: in the lower half of the left half of the main view, input the size of the radiotherapy plan moving bed value, without considering the positive and negative signs before the number. Click on the orientation corresponding to the radiotherapy treatment single, such as left and right, front and back, head and foot direction, click Assign to the upper half of the left half of the calculation function module, and the specific signed value of the moving bed can be displayed in the calculation module. For the initial positioning of the radiotherapy patient, enter the initial accelerator bed value into the initial value module, click calculate, and display the final bed value corresponding to the final tumor center. Click on celar to zero the value of the calculation function module. Click on show to enlarge the result into a separate interface and provide the coordinates to the therapist.

The application relates to an intelligent temperature control moisturizing skin protection device for tumor radiotherapy patients, which comprises an intelligent humidifier body, a telescopic pipe fixedly connected to a liquid outlet of the intelligent humidifier body, a supporting bottom plate, a bearing disc rotatably connected to the surface of the supporting bottom plate, a cross trajectory groove and at least one radial hole formed in the bearing disc, the intelligent humidifier body arranged on the bearing disc, a transmission structure arranged in the supporting bottom plate and an auxiliary structure. The driving member drives the rotating column to continuously rotate, and a set of connecting rod mechanisms are used to convert the rotating motion into specific sector reciprocating swing of the contact wheel, the contact wheel drives the cross trajectory groove on the bearing disc, and finally drives the bearing disc and the intelligent humidifier on the bearing disc to intermittently rotate, so that the output of the moisturizing medium is no longer limited to before and after treatment, but can be continuously carried out during a single treatment lasting for dozens of minutes, and real-time and active protection of the skin is realized.

Provided is a Pt(IV) complex. As a prodrug, the Pt(IV) complex is activated by irradiation to release a Pt(II) complex for the treatment of tumors. Also provided is a pharmaceutical composition including the Pt(IV) complex, and the use of the Pt(IV) complex in the preparation of a drug for treating tumors by means of irradiation activation. Further provided is a kit including the Pt(IV) complex and the description, wherein the description indicates that radiotherapy is performed after administration to treat tumors.

This application relates to the field of biotechnology, specifically disclosing the application of immune cell subsets in the preparation of detection products for assessing the efficacy of neoadjuvant therapy and the risk of recurrence and metastasis in breast cancer. The detection method described in this application is non-invasive and convenient, requiring only peripheral blood, and is easy to repeat sampling and dynamic monitoring. This application also provides a predictive model for the efficacy of neoadjuvant therapy in breast cancer, and a predictive model for the risk of recurrence and metastasis in breast cancer treated with neoadjuvant therapy. The constructed predictive model has a high AUC value (0.82-0.87), and good sensitivity and specificity. Furthermore, through regular postoperative monitoring, abnormal dynamic changes in immune cell subsets can be detected, potentially indicating signs of recurrence earlier than imaging and traditional tumor markers. This helps identify advantageous populations before treatment and high-risk populations after treatment, enabling optimization of treatment plans and individualized adjustment of follow-up density.

The present application relates to the technical field of medical apparatus and instruments, and discloses a neonatal hypothermia portable treatment device and a body temperature regulation system, aiming to solve the problem that the prior art cannot adapt to the transfer scene and is prone to body temperature out of control when a neonatal hypoxic-ischemic encephalopathy is transferred, the body temperature regulation system comprises four modules of information acquisition, temperature control decision, temperature control execution and information connection, the information acquisition module collects and discriminates body temperature, physiological parameters and transfer interference data; the temperature control decision module generates temperature control instructions and interference compensation strategies in combination with preset parameters of body weight and according to scenes; the temperature control execution module drives components to land on the ground according to instructions and feeds back the state; and the information connection module summarizes data and synchronously transfers the data into a hospital admission system, so that the transition body temperature is stably controlled during the transfer, the hospital admission first-aid operation is smoothly connected, and the technical blank of pre-treatment body temperature transition management during short-distance transfer is filled.

The application discloses a kind of information management method and related equipment for thyroid cancer postoperative iodine 131 treatment patient.It comprises: based on the treatment management data of patient, scheduling model is constructed with patient waiting time, medical interaction cost and isolation bed vacancy time as optimization target, and bed capacity constraint, clinical urgency constraint, radiation protection constraint and medical availability constraint are established;Based on the scheduling model and the constraint condition, the joint optimization of patient reservation admission batch, isolation bed allocation and medical communication task is carried out, and the treatment scheduling result is generated;In the case where patient temporary adjustment, bed state change or iodine 131 treatment preparation abnormality is monitored, the treatment scheduling result is dynamically rearranged, so as to execute patient reminder, treatment connection and follow-up management according to the treatment scheduling result after rearrangement.It can solve the problems of low efficiency of reservation and resource coordination, fragmented medical records and lack of dynamic tracking mechanism in traditional information management mode.

The invention discloses a PARP inhibitor sensitivity prediction method based on a specific cell cluster and application. The method comprises the following steps: acquiring an ovarian cancer tumor tissue sample of a subject; detecting whether a specific cell cluster exists in the sample or not, and determining the abundance of the specific cell cluster, wherein the specific cell cluster comprises an IFN epithelial cell cluster CN12 taking an IFN tumor cell as a center and / or a TAM enrichment cluster CN29 taking an M2 type tumor related macrophage as a center; according to the detection result, predicting according to at least one of the following rules: if the CN12 abundance before treatment is greater than 0.8%, the CN29 abundance before treatment is greater than 32.7%, the CN12 abundance after treatment is greater than 0.009%, the CN29 abundance after treatment is greater than 2.9%, or the SPP1 cell density before treatment is greater than 1.7%, predicting that the drug resistance is not sensitive or easily generated. The prediction model is established from a cell cluster space tissue level, and the method has the advantages of high prediction accuracy, flexible sample requirements, high operability and the like.

The invention provides an anus suppository for treating prostatitis and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The anus suppository for treating prostatitis comprises an outer-layer sleeve and suppository contents, wherein the suppository contents comprise a heat-clearing and inflammation-diminishing layer, a warming, dredging and blood-activating layer and a qi-tonifying and kidney-tonifying layer which are sequentially distributed from outside to an inner core, and at least part of the suppository contents are wrapped by the outer-layer sleeve. The outer-layer sleeve prevents a large amount of medicine from being discharged after being released in a short time by delaying initial dissolution of a suppository matrix, and can contain dissolved suppository contents so as to prevent the dissolved suppository contents from flowing out of a body due to rectum peristalsis, so that the effective action time of the medicine is prolonged, and the curative effect of the suppository is improved. The medicine effect of the suppository content is fully exerted, and the use experience of a patient is improved; the medicine components permeate outwards at a controllable speed through the permeation part, the local effective medicine concentration of the rectum is maintained, the suppository matrix is gradually dissolved under the action of body temperature, and the traditional Chinese medicine composition is continuously released.

An example control device for performing a denervation procedure on a patient includes a memory and processing circuitry coupled to the memory. The processing circuitry is configured to receive, from one or more sensors and prior to delivery of neuromodulation therapy via a neuromodulation catheter, pre-therapy sensor data. The pre-therapy sensor data includes one or more parameter measurements for a period of time prior to the delivery of the neuromodulation therapy. The processing circuitry is configured to determine, based on the pre-therapy sensor data, whether the delivery of neuromodulation therapy would cause a deviation, in which the deviation includes one or more patient parameters or device parameters exceeding one or more patient parameter thresholds or device parameter thresholds, and transmit an output based on the determination.

The invention discloses application of ginseng and antler kidney tonifying tablets in preparation of drugs for preventing and / or treating prostatic hyperplasia. The ginseng antler kidney-tonifying tablet has a good treatment effect on prostatic hyperplasia, the treatment effect is remarkable, no operation is needed, the ginseng antler kidney-tonifying tablet belongs to new use of an old medicine, the safety is high, the side effect is small, and the production cost is greatly reduced. The problems that current western medicines for treating benign prostatic hyperplasia are long in medication cycle, large in toxic and side effects and limited in clinical application are solved. Experimental results show that the ginseng and antler kidney-tonifying tablet can reduce the prostate gland coefficient; the androgen level of a prostatic hyperplasia patient is reduced; the gland and glandular cavity expansion and hyperplasia degree of a prostatic hyperplasia patient is improved.

Provided in the present invention is a method for constructing a sensitivity prediction model for neoadjuvant chemotherapy of advanced pharyngolaryngeal cancer. A prediction model is constructed by means of identifying genes of patients with advanced pharyngolaryngeal cancer before neoadjuvant chemotherapy, which genes are differentially expressed in both a sensitive group and a resistant group and in cancerous tissues and adjacent normal tissues. The model can predict, before treatment, the sensitivity of patients to neoadjuvant chemotherapy, so as to identify chemotherapy responders, and can design individualized treatment plans for the patients, so as to perform precise treatment, thus retaining the pharyngolaryngeal function of the patients to the greatest extent while ensuring or improving the survival rate, thereby greatly improving the quality of life of the patients. At present, the prediction model is undergoing a multi-center prospective study, which helps to promote the model more widely and realize earlier clinical translation.

1. The name of the design product: disposable surgical instruments for treating benign prostatic hyperplasia. 2. The use of the design product: medical instruments for minimally invasive treatment of benign prostatic hyperplasia by condensing steam. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view.

The invention relates to the technical field of medical image processing. The invention discloses a habitat imaging-based gastric cancer neoadjuvant chemotherapy curative effect prediction method and a habitat imaging-based gastric cancer neoadjuvant chemotherapy curative effect prediction system, and the method comprises the following steps: S1, obtaining pre-treatment CT and clinical pathology information, and marking the maximum tumor area and upper and lower layers; s2, dividing the marked region into habitat sub-regions with different biological characteristics through habitat imaging; and S3, performing prognosis analysis on the habitat subregion, screening independent prognosis features related to survival, and generating a habitat subregion image. And S4, constructing a joint attention model, inputting images of the marked area and the habitat subarea, predicting the curative effect and the total lifetime, and obtaining a survival score. And S5, integrating clinical pathological information and survival scores, performing prognosis analysis, constructing a column graph, and evaluating correlation. After a CT image label before treatment is obtained, habitat imaging is used for dividing subareas, related images are generated, the model is input in a combined mode, tumor heterogeneity is revealed, and the curative effect is predicted.

The present disclosure provides apparatus and methods to both infer stent expansion (vessel expansion or compliance) and probability of procedural success (vessel patency) from pretreatment diagnostic imaging at the point-of-care and also train an inference model to generate such an inference, thus allowing a physician to choose with greater certainty an optimal treatment tool and treatment protocol for treating a vessel of a patient.

A method for radiotherapy treatment plan verification during a fraction of an online adaptive radiotherapy treatment The method comprises obtaining a pre-treatment cone beam computed tomography, CBCT, image of a patient. The method further comprises adapting a treatment plan, based on the CBCT image. The method further comprises delivering a first portion of the adapted treatment plan to the patient. The method further comprises obtaining dose data from the delivery of the first portion. The method further comprises determining a dosimetric value associated with quality assurance of the adapted treatment plan, based on the dose data. If the dosimetric value is within an acceptable range, the method further comprises delivering a second portion of the adapted treatment plan. Or, if the dosimetric value is outside the acceptable range, the method further comprises stopping the delivery of the adapted treatment plan.

This invention discloses a metabolomics-based method for predicting the efficacy of non-invasive pretreatment intervention (NAIC) in gastric cancer and specific metabolites, belonging to the field of biodetection technology. The method includes: obtaining plasma samples from gastric cancer patients before treatment, detecting the abundance of their metabolites, and obtaining baseline plasma metabolomics data; classifying patients into a response group and a non-response group based on post-treatment imaging assessment results; comparing the baseline metabolomics data of the two groups to screen for differentially expressed metabolites; using these differentially expressed metabolites as features, training the model using LASSO regression, determining the optimal parameters through cross-validation, and constructing an efficacy prediction model composed of specific metabolites and their regression coefficients; for the sample to be predicted, detecting the abundance of its specific metabolites and inputting them into the model to obtain a risk score, and predicting the patient's response to treatment by comparing it with a risk threshold. This invention enables accurate efficacy prediction before treatment, providing an important basis for individualized clinical treatment decisions.

The morphology of an anatomical target is monitored using ultrasound to confirm when the anatomical target's morphology is substantially aligned, or otherwise in agreement, with a reference morphology indicated by a radiation treatment plan and determined from pre-treatment ultrasound data. Ultrasound data are acquired to measure and monitor the morphology of an anatomical target, such as the bladder, rectum, stomach, or the like. The ultrasound data are compared to reference data. When the morphology of the anatomical target is substantially aligned, or otherwise in agreement, with the anatomical morphology indicated by the reference data and the radiation treatment plan, then the patient can be provided with the planned radiation treatment for that day.

A digital treatment program for trauma and PTSD is disclosed along with the methods implemented by the program. This program, method and protocol include pre- and post-treatment assessments to measure progress and detect potential problems, and includes a number of eye movement and exposure therapy sessions. Throughout the sessions, the patient is enabled to access grounding tools, and then optionally return to the session, which reduces the difficulties faced by the patient while going through the protocol, promoting completion of the protocol. The assessments, responses and progress of the patient are recorded and stored in a database and can be accessed by a caregiver, who monitors the treatment and progress by the patient. Apparatus is also disclosed to implement the digital treatment program.

The present application provides a method for multi-omics processing through radiotherapy data of a head and neck cancer patient, wherein multi-omics is applied to pre-treatment evaluation of radiotherapy re-planning needs of the head and neck cancer patient, comprising the following steps: (1) pre-processing of radiotherapy patient data of a head and neck cancer patient, the radiotherapy patient data comprising radiotherapy data and clinical feature data of the patient; (2) extracting multi-omics features from the pre-processed radiotherapy patient data; (3) estimating or predicting the RTR needs of the head and neck cancer patient by fitting the extracted multi-omics features based on a prediction model. The present application allows for "pre-treatment" identification of patients at risk for RTR, so that doctors can be aware of these patients in advance and better allocate resources for them. The present application does not change the dose and / or coverage of the tumor during radiotherapy; the patient will still experience changes in his anatomy (volume and position of organs) during radiotherapy, as this is a natural reaction of the organs when they are irradiated during radiotherapy.

Medical systems are described, including a medical system that includes a sheath and a catheter. The sheath is configured to be positioned within a urethra of a patient. A proximal portion of the sheath includes a port configured to receive one or more fluids. The catheter is insertable into the sheath and configured to be movably positioned within the sheath in the urethra. A distal portion of the catheter includes one or more ultrasound transducers configured to perform ultrasound imaging of at least a portion of a prostate of the patient.

This specification describes variations of methods for monitoring and / or tracking a region of interest within a patient during a radiotherapy session. For example, a method for monitoring a region of interest may include comparing an image of the target region acquired during real-time radiation delivery with a reference image of the same target region acquired before treatment delivery and determining the difference between the two images. If it is determined that the treatment image differs from the reference image, radiation delivery may be stopped to prevent radiation from being delivered to healthy tissue as a result of an anatomical shift in the target region. This specification also describes systems that may be used to implement such methods.

Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and / or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and / or reverse, AD symptoms.

Method for determining the effect of a selected treatment administered to a patient, which includes the procedures of acquiring VOC-emission-data of pre-treatment-target-cells-cultures and producing a pre-treatment-target cells-VOC-profile from the VOC-emission of the pre-treatment-target-cells-cultures. Producing an MCD-target-cells-VOC-profile by: (a) inducing MCD on non-treated target-cells-cultures thereby producing post-MCD-target-cells-cultures; and (b) acquiring VOC-emission-data of the post-MCD-target-cells-cultures. Applying the selected treatment to target-cells-cultures and acquiring VOC-emission-data of post-treatment-target-cells-cultures and determining the effect of the selected treatment. The treatment is determine as effective when: (a) concentration values from VOC-emission-data of pre-treatment-target-cells-cultures, of VOCs associated with the pre-treatment-target-cells-VOC-profile, are greater than concentration values from the VOC-emission-data of post-treatment-target-cells-cultures, of VOCs associated with the pre-treatment-target-cells-VOC profile; and (b) concentration values from VOC-emission-data of post-treatment-target-cells-cultures, of VOCs associated with the MCD-target-cells-VOC-profile, emitted by the post- treatment-target-cell-cultures, are greater than concentration values from the VOC-emission-data of pre-treatment-target-cells-cultures, of VOCs associated with the MCD-target-cells-VOC-profile, emitted by the pre-treatment-target-cell cultures.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

The invention discloses a biomarker combination, application, a product and a system for detecting local progression stage gastric cancer, and relates to the technical field of biological medicines. The biomarker combination for diagnosis, screening, illness state monitoring and / or drug curative effect monitoring of the local progression stage gastric cancer comprises the following proteins: SRI, SMARCA5, TPD52, PLBD1, PDLIM7, COL18A1, ACTR3, ALDH1A1, EHD2, ARF5, DNPEP, OGFR, PBXIP1, GOT1, SNW1, PRKAR1A, DCTN2, TMEM109, ANPEP and MOV10. According to the invention, a 20-panel proteome prediction model is constructed for the first time, and compared with PDL1 expression, the 20-panel proteome prediction model has better capability of predicting treatment response crowds. Compared with PDL1 expression which is most commonly used for judging the curative effect of gastric cancer immunotherapy clinically at present, the sensitivity, the specificity, the AUC and the like of the 20-Panel proteome for predicting pathological response people are obviously improved. The method is beneficial for efficiently and accurately predicting and screening sensitive people who receive neoadjuvant chemotherapy and immunotherapy on the gastric cancer in the local development stage before treatment, and the most suitable treatment scheme is selected.

The invention discloses a method for evaluating iodine therapy response after total resection of papillary thyroid carcinoma by using a serum protein scoring system before radioiodine therapy, and develops a combined diagnosis model (FASLG, CXCL12 and HGF) for predicting iodine therapy response by measuring serum samples before radioiodine therapy after total resection of papillary thyroid carcinoma patients. The system is a scoring system for predicting curative effect response, and if the score is high, the treatment response is poor. By detecting the content of the combined diagnosis model protein marker in the serum sample of the patient, the patient with poor radioiodine treatment effect can be screened, and a patient layering method and an advanced intervention time window are provided, so that other intervention treatment is carried out before radioiodine treatment, and the life quality of the patient is improved.

The invention discloses a comprehensive prediction model for predicting treatment drug resistance of hepatocellular carcinoma patients and a construction method and application thereof. The method comprises the following steps: acquiring clinical index data and serum glycomics characteristic data of a hepatocellular carcinoma patient before treatment; screening out key clinical indexes and key carbohydrate chain features significantly related to drug resistance, and integrating the key clinical indexes and the key carbohydrate chain features into a joint feature vector; and training to obtain a comprehensive prediction model through a logistic regression algorithm by using the combined feature vector and the corresponding drug resistance state tag. The invention also provides a prediction system comprising the model, and a special kit for generating standardized saccharomics characteristic data. Through fusion of macroscopic clinical information and microscopic carbohydrate chain molecular information, the combined prediction model constructed by the invention significantly improves prediction precision, can noninvasively and early evaluate the risk of primary or secondary drug resistance of a patient before treatment, and provides a reliable decision basis for clinically formulating an individualized treatment scheme.

The invention belongs to the technical field of nuclear medicine, and particularly relates to a compound targeting CAIX and PSMA as well as a nuclide marker, a preparation method and application of the compound. One purpose of the present invention is to provide an application of a compound targeting CAIX and PSMA or a salt thereof in preparation of a product for diagnosis or / and treatment of prostate cancer, prostate cancer before metastasis, colon cancer, breast cancer, kidney cancer or bladder cancer. The compound and the nuclide marker thereof have multiple advantages in diagnosis and treatment of tumors expressing PSMA and CAIX, including high affinity to two receptors, high target / non-target ratio (T / NT) and good in-vivo distribution characteristics, so that a more reliable imaging tool is provided for early detection and precise treatment of tumors.